Project Grant R21AR086811
- Federal Project Grant Award Summary The University of Rochester received a $464,315 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective July 1, 2025, through June 30, 2030. This research initiative investigates the role of L-type calcium channel CAV1.2 in Achilles tendinopathy, a degenerative tendon condition associated with pain and...
- Federal Grant Award Summary The University of Rochester received a $600,000 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded September 5, 2025, with completion targeted for August 31, 2026. This grant funds research aimed at deciphering the cellular and molecular signatures of psoriatic arthritis (PSA) non-response using a humanized murine model. The research will identify tissue-specific...
- Federal Project Grant Award Summary The University of Rochester received a $1.68M project grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 1, 2025 through August 31, 2028. This award funds research into the pathophysiology of tubular aggregate myopathy (TAM), an inherited muscle disease characterized by progressive weakness, exercise...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,034 Project Grant to the University of Nebraska Medical Center on August 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research initiative, with a completion date of June 30, 2030, focuses on identifying molecular and epidemiologic determinants of myocardial dysfunction and heart failure (HF) in patients with...
- Federal Project Grant Award Summary The University of Rochester received a $332,792 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective May 1, 2026 through April 30, 2031. This five-year research initiative, titled "Drivers of Repeat Instability in Myotonic Dystrophy," delivers scientific research and investigation services focused on...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded $382,537 to The Regents of the University of Colorado-Denver on August 1, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for a five-year research project extending through July 31, 2030. The primary deliverable is basic and translational research investigating the pathogenic roles of Granzyme K-expressing CD8 T cells in...
- Federal Project Grant Award Summary Augusta University Research Institute, Inc. (AURI) received a $177,120 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 1, 2025, through August 31, 2030. The award funds research to evaluate the predictive validity and clinical utility of the Fracture Risk Assessment Tool (FRAX-U.S.) in assessing 10-year...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $529,616 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective June 1, 2025, with a completion date of May 31, 2030. The award funds research to define the role of Notch-driven fibrogenesis in treatment failure in rheumatoid arthritis (RA), specifically investigating...
- Federal Grant Award Summary The University of California, San Francisco received a $1,031,877 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective July 1, 2025, through April 30, 2030. This award supports research investigating the role of endogenous retroviruses (ERVs) in rheumatoid arthritis (RA) pathogenesis, with particular focus on identifying...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded New Jersey Institute of Technology a $330,107 Project Grant effective September 1, 2025, through June 30, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award supports fundamental research investigating the role of stress anisotropy—directional stress differences in extracellular matrices—in fibroblast activation and its...
The University of Rochester received a $342,125 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for the period May 1, 2026 through April 30, 2028. The grant funds research investigating the role of telocytes in the synovial lymphatic system and their relationship to rheumatoid arthritis (RA) pathogenesis. The research will examine how telocyte networks interact with mast cells to regulate lymphatic function and inflammatory responses in joint tissue, with particular focus on how exercise may preserve these cellular networks and mitigate RA-associated inflammation. The project deliverables include two primary research aims utilizing advanced microscopy techniques to characterize telocyte networks in the synovium and joint-draining lymphatic vessels, and to assess the protective effects of exercise on telocyte preservation and lymphatic function in inflammatory arthritis models. Outputs will include whole-mount immunofluorescent microscopy and light-sheet microscopy data examining telocyte network architecture in healthy and diseased states, as well as experimental findings on exercise-mediated prevention of telocyte loss and lymphatic dysfunction. The research is expected to generate peer-reviewed publications and preclinical data contributing to the mechanistic understanding of lymphatic dysfunction in RA and potential therapeutic applications.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $342.1k | 4/28/26 |